Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy (Q37878396)

24 August 2017

1 reference

title

Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

Anthony H Barnett

1

1 reference

PubMed ID

21603986

24 August 2017

language of work or name

English

0 references

publication date

17 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

28

1 reference

24 August 2017

6

1 reference

24 August 2017

447-459

1 reference

https://scigraph.springernature.com/pub.10.1007/s12325-011-0028-y

24 August 2017

0 references

cites work

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Glycemic status and development of kidney disease: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0028-Y

10.1007/S12325-011-0028-Y

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21603986